Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

MIRA Pharmaceuticals, Inc. - Common Stock (NQ:MIRA)

1.400 -0.050 (-3.45%)
Streaming Delayed Price Updated: 10:02 AM EDT, May 19, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about MIRA Pharmaceuticals, Inc. - Common Stock

< Previous 1 2 3 4 5 Next >
MIRA Pharma Stock Soars To 2-Month High On $60M SKNY Deal: Retail Sentiment Strong
Retail sentiment on Stocktwits surged, with users expressing optimism about the merger’s success, despite a pullback in after-hours trading. 
Via Stocktwits
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Via Benzinga
MIRA Pharmaceuticals Announces Board Approval of SKNY Acquisition Reflecting $60+ Million in Combined Enterprise Value Based on Independent Review
Via ACCESS Newswire
EXCLUSIVE: Mira Pharmaceuticals Board Approves SKNY Pharma Acquisition, Establishing Combined Enterprise Value Over $60 Million
Mira Pharmaceuticals to acquire SKNY in a stock-based deal valuing both firms near $30 million each, backed by third-party pipeline valuation reports. 
Via Benzinga
MIRA Pharmaceuticals Reports No Brain Toxicity in FDA-Required Study of Ketamir-2, Confirming Absence of Ketamine-Linked Neurotoxicity
Via ACCESS Newswire
MIRA Pharmaceuticals Validates Ketamir-2's Safety Profile With No Adverse Findings, Paving the Way for IND Submission by Year-End
Via ACCESSWIRE
MIRA Reveals Innovative Phase I/IIa Protocol Design and Selection of Clinical Trial Site
Via ACCESSWIRE
EXCLUSIVE: MIRA Pharmaceuticals Lead Program Ketamir-2 Shows No Brain Toxicity In FDA-Mandated Study
Ketamir-2 from MIRA Pharmaceuticals showed no brain toxicity in rats, meeting FDA study requirements and advancing its clinical development program. 
Via Benzinga
Exposures Product Safety
On Wednesday, there are stocks with unusual volume. Let's take a look.
These stocks have an unusual volume in today's session 
Via Chartmill
MIRA Pharmaceuticals Reports Positive In Vitro Drug Release Data for Topical Ketamir-2, Targeting $11B+ U.S. Topical Pain Relief Market and Exploring FDA Fast Track Designation
Via ACCESS Newswire
12 Health Care Stocks Moving In Thursday's Intraday Session
Via Benzinga
Is Mira Pharmaceuticals Gaining or Losing Market Support?
Via Benzinga
Mira Pharma Leads Healthcare Buzz Surge On Promising Oral Ketamine Analog Preclinical Trial
The drug outperformed standard treatments like pregabalin and gabapentin in prior studies and has shown a favorable safety profile without ketamine's psychedelic effects. 
Via Stocktwits
12 Health Care Stocks Moving In Wednesday's Intraday Session
Via Benzinga
Which stocks are gapping on Wednesday?
The market is filled with gapping stocks in Wednesday's session. Let's discover which stocks are showing gap-ups and gap-downs. 
Via Chartmill
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Via Benzinga
MIRA Pharmaceuticals Announces Positive Results for Ketamir-2 in Diabetic Neuropathy Animal Model, Reinforcing Confidence Ahead of Phase I Completion
Via ACCESS Newswire
EXCLUSIVE: MIRA Pharmaceuticals Ketamir-2 Shows Efficacy In Diabetes-Associated Nerve Damage In Animal Study
MIRA's Ketamir-2 shows promise in treating diabetic neuropathy, with a Phase 2a trial expected by late 2025 and human data in early 2026. 
Via Benzinga
MIRA Pharmaceuticals Enrolls First Subjects in Phase 1 Clinical Trial of Ketamir-2 for Neuropathic Pain
Via ACCESS Newswire
MIRA Pharmaceuticals Signs Binding Letter of Intent to Acquire SKNY Pharmaceuticals, Securing a $5 Million Capital Infusion to Advance Weight Loss and Smoking Cessation Drug Development
Via ACCESS Newswire
EXCLUSIVE: MIRA Pharmaceuticals Signs To Acquire SKNY Pharmaceuticals, Expand Pipeline Into Weight Loss And Smoking Cessation Drug
MIRA Pharmaceuticals signs letter of intent to acquire SKNY Pharmaceuticals, adding SKNY-1, a preclinical drug for weight loss and smoking cessation, to its portfolio. 
Via Benzinga
MIRA Pharmaceuticals Expands Ketamir-2 Development with Topical Treatment for Localized Neuropathic and Inflammatory Pain
Via ACCESS Newswire
EXCLUSIVE: MIRA Pharmaceuticals Expands Pipeline, Enhances Value Proposition With Development Of Topical Formulation For Lead Pain Treatment Candidate
MIRA Pharmaceuticals unveils Ketamir-2 topical for neuropathic pain, complementing its oral version. Clinical and preclinical studies are advancing this year. 
Via Benzinga
MIRA Pharmaceuticals Announces Approval and Initiation of Phase 1 Clinical Trial for Ketamir-2 in Neuropathic Pain
Via ACCESS Newswire
EXCLUSIVE: MIRA Pharmaceuticals Kick Starts Human Trial In Israel For Ketamir-2 For Neuropathic Pain
MIRA Pharmaceuticals gains approval for a Phase 1 trial of Ketamir-2 in Israel, aiming to complete by Q4 2025 before moving to Phase 2a in neuropathic pain. 
Via Benzinga
MIRA Pharmaceuticals Submits IND for Ketamir-2 to FDA, Marking a Significant Milestone in the Company's Pipeline Development
Via ACCESSWIRE
EXCLUSIVE: MIRA Pharmaceuticals Files FDA Application To Start Human Trials For Its Lead Pain Treatment
MIRA Pharmaceuticals submits an IND for Ketamir-2, aiming to treat neuropathic pain with 100% pain reversal shown in preclinical studies. 
Via Benzinga
Exposures Product Safety
EXCLUSIVE: MIRA Pharmaceuticals Validates Ketamir-2's Safety Profile, Paving Way For Human Trials In Neuropathic Pain
MIRA Pharmaceuticals completes preclinical safety studies for Ketamir-2, confirming no adverse findings as it targets an Investigational New Drug submission by late 2024. 
Via Benzinga
MIRA Pharmaceuticals' Formulated Shows Greater Efficacy Than FDA-Approved Drug For Chemo-Induced Neuropathic Pain
MIRA Pharmaceuticals stock rises as new preclinical data reveal its oral ketamine analog Ketamir-2 is 60% more effective than gabapentin in pain relief. 
Via Benzinga
12 Health Care Stocks Moving In Monday's Pre-Market Session
Via Benzinga
< Previous 1 2 3 4 5 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.